Art. 10a Directive (EU) 2001/83

In forcesince 26 Jan 2007cited 22×

By way of derogation from Article 8(3)(i), and without prejudice to the law relating to the protection of industrial and commercial property, the applicant shall not be required to provide the results of pre-clinical tests or clinical trials if he can demonstrate that the active substances of the medicinal product have been in well-established medicinal use within the Community for at least ten years, with recognised efficacy and an acceptable level of safety in terms of the conditions set out in Annex I. In that event, the test and trial results shall be replaced by appropriate scientific literature.

The 10 that are cited most themselves, of 22.

  • Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…166Law

    … 3, artikel 10, 10a, 10b og 11 eller artikel 32, stk. 5, i direktiv 2001/83/EF og bilag I hertil eller i artikel 9, stk. 4, i denne forordning. Navnlig underretter indehaveren af markedsføringstilladelsen straks agenturet og Kommissionen …

  • Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…9Law

    Články 7 a 8 se nepoužijí na přípravky registrované podle článků 10, 10a, 13 až 16 nebo 16a až 16i směrnice 2001/83/ES.

  • Judgment of the Court (Fifth Chamber), 23 October 2014. Olainfarm AS v Latvijas Republikas Veselības ministrija and Zāļu valsts aģentūra.Decision

    In those circumstances, the Augstākās Tiesas Senāts (Senate of the Supreme Court), decided to stay the proceedings and to refer the following questions to the Court for a preliminary ruling: On a proper construction of Article 10 or of …

    23 Oct 2014 · 62013CJ0104

  • Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 Decembe…1Law

    … léčivých přípravků registrovaných podle tohoto nařízení, které splňují jeden z požadavků stanovených v článcích 10 a 10a směrnice 2001/83/ES, se vztahují postupy uvedené v čl. 107m odst. 3 až 7, článcích 107n až …

  • Arrêt du Tribunal (cinquième chambre) du 11 décembre 2014. PP Nature-Balance Lizenz GmbH contre Commission européenne.Decision

    Bei der Auslegung des Art. 10a der Richtlinie 2001/83 ist zunächst generell zu berücksichtigen, dass Bestimmungen, die Ausnahmen von einem allgemeinen Grundsatz darstellen, nach ständiger Rechtsprechung eng auszulegen sind (Urteil des …

    11 Dec 2014 · 62013TJ0189

  • Judgment of the Court (Second Chamber) of 14 March 2018. Proceedings brought by Astellas Pharma GmbH.Decision

    Article 19(1) of Directive 2001/83 provides that, in order to examine the application submitted in accordance with Articles 8, 10, 10a, 10b and 10c, the competent authority of a Member State must verify whether the particulars submitted in …

    14 Mar 2018 · 62016CJ0557

  • Arrêt de la Cour (huitième chambre) du 3 décembre 2015. PP Nature-Balance Lizenz GmbH contre Commission européenne.Decision

    À l’appui de son pourvoi, Nature-Balance soulève, en substance, trois moyens. Les deux premiers moyens sont respectivement pris d’une violation des articles 116 et 10 bis de la directive 2001/83. Le troisième moyen est tiré d’une …

    3 Dec 2015 · 62015CJ0082

  • Opinion of Advocate General Wahl delivered on 20 May 2014. Olainfarm AS v Latvijas Republikas Veselības ministrija and Zāļu valsts aģentūra.Decision

    In those circumstances, the Augstākās tiesas Senāts decided to stay the proceedings and to refer the following questions to the Court for a preliminary ruling: On a proper construction of Article 10 or of any other provision of …

    20 May 2014 · 62013CC0104

  • Judgment of the General Court (Fifth Chamber), 4 July 2013. Laboratoires CTRS v European Commission.Decision

    It is clear from the second recital in the preamble to the contested decision that the MA application submitted by the applicant was made under Article 10a of Directive 2001/83/EC of the European Parliament and of the Council of 6 November …

    4 Jul 2013 · 62012TJ0301

  • Opinion of Advocate General Sharpston delivered on 22 April 2010. European Commission v Republic of Lithuania.Decision

    That can be derived from the fact that, in Regulation No 726/2004, recital 14 provides that the quality, safety and efficacy criteria laid down in Directives 2001/82 and 2001/83 are to apply to medicinal products authorised by the …

    22 Apr 2010 · 62008CC0350